The NoA includes claims directed to the use of Zertane with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED to address concurrent premature ejaculation (PE) and ED.
Additionally, the allowed claims also include composition of matter claims, such as claims directed to a pharmaceutical composition or a kit containing Zertane and a PDE5 inhibitor.